Todd Borland

Todd Borland has worked in the biotechnology and pharmaceutical industry since 2002. Todd began their career as a Research Technician at Penn State University, where they managed day to day operations of the laboratory and carried out a research project examining the interactions of a viral protein with both viral and cellular proteins. In 2006, they joined Alnylam Pharmaceuticals as a Senior Research Associate, where they supported in-vitro and in-vivo experiments for the selection of a lead siRNA targeting RSV, developed a GLP-validated ELISA, and screened siRNAs in rodent models. In 2010, they became a Scientist at Novartis, where they implemented an immunostain plaque assay to quantify Influenza viral titers and characterized RNAi enhancer compounds using in-vitro assays. From 2014 to 2016, they worked at Biogen as a Research Associate III, where they validated tool compounds against integrin targets using a variety of in-vitro assays including FACS and developed a qPCR assay to interrogate integrin biology and signaling. From 2016 to 2018, they worked at CRISPR Therapeutics as a Scientist and Senior Research Associate. Currently, they are employed as a Scientist at Amagma Therapeutics.

Todd Borland attended Mars Area High School and then went on to earn a Bachelor of Science in Microbiology and Biochemistry from Penn State University in 2002.